Aligos Therapeutics Reports Strong Q4 2025 Results, Extends Cash Runway, and Advances Pipeline
ALGS sits 91% above its 52-week low of $3.76.
Summary
Aligos Therapeutics announced strong Q4 2025 financial results with a significantly reduced net loss, an increased cash position of $77.8 million, and an extended cash runway into Q3 2026, alongside positive pipeline progress.
Key Events · Earnings and Guidance · ALGS
-
Strong Q4 2025 Financial Performance
Reported a net loss of $(1.91) per share for Q4 2025, a substantial improvement from $(13.08) in Q4 2024, and significantly reduced full-year net loss to $(2.45) per share from $(20.94) in 2024.
-
Extended Cash Runway
Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, an increase from $56.9 million in 2024, and are expected to fund operations into the third quarter of 2026.
-
Pipeline Advancement in HBV
Completed planned enrollment for HBeAg- participants in the Phase 2 B-SUPREME study for pevifoscorvir sodium and advanced ALG-170675, a dual-mechanism ASO, into IND-enabling studies with partner funding for China.
-
Positive Preclinical Data for Obesity/MASH Program
ALG-055009 demonstrated synergistic weight loss in combination with incretin receptor agonists in preclinical models, with evaluation of out-licensing options ongoing.
Analysis · ALGS · Life Sciences
Aligos Therapeutics reported significantly improved financial results for Q4 and full year 2025, substantially reducing its net loss. The company's cash, cash equivalents, and investments increased to $77.8 million, providing sufficient funding into Q3 2026, a critical factor for a clinical-stage biotechnology company. This financial stability is complemented by positive pipeline advancements, including the completion of planned enrollment for a key Phase 2 study, the progression of a dual-mechanism ASO into IND-enabling studies, and promising preclinical data for an obesity/MASH candidate. The appointment of a Chief Commercial Officer also signals future strategic planning. This 8-K provides comprehensive details following an initial news report on the Q4 loss per share.
At the time of this filing, ALGS was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $3.76 to $14.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.